Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theraflu Thin Strips is a line of over-the-counter (OTC) cold and cough medications developed by Novartis Consumer Health. The product line is distinguished by its novel thin film dosage form, which dissolves on the tongue without the need for water, facilitating convenient systemic delivery. The line includes several variants with different active ingredients: the Long Acting Cough variant contains dextromethorphan (a cough suppressant); the Multi-Symptom variant contains diphenhydramine (an antihistamine); and the Nighttime Cold and Cough variant contains a combination of diphenhydramine and phenylephrine (a nasal decongestant). Dextromethorphan suppresses cough by acting on the cough center in the medulla; diphenhydramine blocks H1 histamine receptors to relieve allergy-like symptoms and provide sedation; and phenylephrine acts as an alpha-1 adrenergic agonist to reduce nasal congestion through vasoconstriction. Launched in the mid-2000s, it was the first systemic medication available in a thin film format.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Theraflu Thin Strips.